http://orcid.org/0000-0002-7317-9107
References
- Fernandez-Gomez J, Madero R, Solsona E, et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol. 2009;182(5):2195–2203.
- Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466–475.
- Racioppi M, Cappa E, D’Agostino D, et al. Size of bladder cancers: correlation among different types of measurement. Urol Int. 2013;90(2):191–194.
- De La Pena E, Hernandez V, Blazquez C, et al. Weight of the resected specimen after transurethral resection as a new predictive variable for recurrence of non-muscle-invasive bladder tumour. BJU Int. 2013;111(4 Pt B):E196–E201.
- Kwon DH, Song PH, Kim HT. Multivariate analysis of the prognostic significance of resection weight after transurethral resection of bladder tumor for non-muscle-invasive bladder cancer. Korean J Urol. 2012;53(7):457–462.
- Sobin Lh GM, Wittekind C. TNM classification of malignant tumors. UICC international union against cancer. 7th ed. Hoboken (NJ): Wiley-Blackwell; 2009.
- Montironi R, Mazzucchelli R, Scarpelli M, et al. Morphological diagnosis of urothelial neoplasms. J Clin Pathol. 2007;61(1):3–10.
- Sauter G, Amin M. Tumours of the urinary system: non-invasive urothelial neoplasias. In: Eble JN, Sauter G, Epstein JI, et al., editors. WHO classification of tumours of the urinary system and male genital organs. Lyon: IARCC Press; 2004.
- Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics. 2000;56(2):337–344.
- Jarvinen R, Kaasinen E, Sankila A, et al. Long-term efficacy of maintenance bacillus Calmette-Guerin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up. Eur Urol. 2009;56(2):260–265.
- Huncharek M, McGarry R, Kupelnick B. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis. Anticancer Res. 2001;21(1B):765–769.
- Malmstrom PU, Sylvester RJ, Crawford DE, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. Eur Urol. 2009;56(2):247–256.
- Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, et al. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol. 2000;163(1):73–78.
- Hatano T, Oda M, Ogawa Y, et al. Exact documentation of location and size of bladder tumor with a three-dimensional mapping device. Int J Urol. 1996;3(1 Suppl):S46–S47.
- EAU Guidelines. Edn. presented at the EAU Annual Congress Copenhagen 2019. ISBN 978-94-92671-04-2. http://uroweb.org/guidelines/compilations-of-all-guidelines/
- Ravvaz K, Walz ME, Weissert JA, et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in a United States population. J Urol. 2017;198(4):824–831.